

## ERG (Clone: EP111) Rabbit Monoclonal Antibody

<b>PRODUCT INFORMATION:</b>	<b>PERFORMANCE CHARACTERISTICS:</b>
PR044 6ml Ready to use	<b>Localization:</b> Nucleus
PR044 3ml Ready to use	<b>Retrieval Buffer:</b> Tris-EDTA, pH 9.0
CR044 1ml Concentrated	<b>Incubation:</b> 30-60 minutes
CR044 0.5ml Concentrated	<b>Positive control:</b> Prostate Carcinoma
CR044 0.1ml Concentrated	
HAR044 6ml Ready to use	
HAR044 3ml Ready to use	

**Host, Isotype:** Rabbit, IgG

### STORAGE AND HANDLING

**Storage Recommendations:** Store at 2-8°C. When stored at the appropriate conditions, the antibody is stable until expiry. Do not use the antibody after expiration date provided on the vial in any condition.

To ensure proper reagent delivery and stability, replace the dispenser cap after every use and immediately place the vial into the refrigerated conditions in an upright position. The contents of the vial should be used within 9 months from the opening of the vial.

### SPECIMEN PREPARATION

#### Staining Recommendations:

Routinely processed, FFPE tissues are suitable for use with this primary antibody, when used PathnSitu's Poly Excel HRP/DAB detection system. The recommended tissue fixative is 10% neutral buffered formalin. Variable results may occur as a result of prolonged fixation or special processes such as decalcification. Thickness of the sections should be 2-5µm. Slides should be stained once the sections are made as antigenicity of the cut sections may diminish over a period of time. It is recommended to stain known positive and negative controls simultaneously with unknown specimens.

### PRECAUTIONS

1. This product should be used by qualified and trained professional users only
2. The product contains < 0.1% of sodium azide as preservative and is not classified hazardous, refer MSDS for further details
3. As with any product derived from biological sources, proper handling procedures should be used
4. Do not use reagents after expiration date
5. Use protective clothing and gloves, while handling reagents
6. All hazardous materials should be disposed according to local state and federal regulations
7. Avoid microbial contamination of reagents as it may lead to incorrect results

### STAINING PROCEDURE

**Antigen Retrieval Solution:** Use Tris-EDTA Buffer (Cat#PS009) as antigen retrieval solution.

**Heat Retrieval Method:** Retrieve sections under steam pressure for 15 minutes using PathnSitu's MERS (Multi Epitope Retrieval System) for optimal retrieval of the epitopes, allow solution to cool at the room temperature, transfer the tissue sections/slides to the distilled water prior to the primary antibody application.

**Primary Antibody:** Cover the tissue sections with primary antibody and incubate for 30-60 min at room temperature when used PathnSitu's PolyExcel Detection System.

**Detection System:** Refer to PathnSitu's PolyExcel HRP/ DAB detection system protocol for optimal staining results.

### QUALITY CONTROL

The recommended positive tissue control for ERG is Prostate Carcinoma. A positive and negative tissue control must be run with every staining procedure performed for monitoring the correct performance of processed tissue and test reagents. A negative tissue controls provide an indication of non-specific background staining. If the results are not expected in positive and negative controls the test must be considered invalid and entire procedure must be cross verified. Individual laboratory must establish their own quality control to validate the process and antibody when opened a vial.

### INTERPRETATION OF RESULTS

ERG stains the Nucleus. A qualified experienced/trained pathologist must interpret the results in the patient's sample along with the positive and negative controls.

### PERFORMANCE CHARACTERISTICS

PathnSitu products will undergo a thorough quality control check before it is released to the market. The antibody showed consistent specific and sensitive staining on the multiple positive tissue controls tested, by inter run, intra run and lot based studies. The antibody is stable for the expiry mentioned on the labels which is determined by real time or accelerated methods.

### INTENDED USE

#### For *in vitro* diagnostic use only

This antibody is intended for use in qualitatively identify ERG antigen by light microscopy in formalin fixed, paraffin embedded (FFPE) tissue sections using immunohistochemical (IHC) detection methodology. Interpretation of any positive or negative staining must be complemented with the evaluation of proper known controls (Positive and Negative) and must be made within the context of the patient's clinical history and other diagnostic tests. A qualified and trained pathologist must perform evaluation of the test. This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using nonimmunologic histochemical stains.

### SUMMARY AND EXPLANATION

ERG, the ETS related gene, belongs to the ETS family that plays important roles in cell development, differentiation, proliferation, apoptosis and tissue remodeling. This family of transcription factors contains approximately 30 members of that share a highly conserved DNA-binding domain (ETS domain) and differs from each other in other domains (such as absence or presence of the Pointed/SAM domain) and are thus distinguished in sub-families. The aberrant expression of several ETS proteins is involved in tumor development and progression. ERG belongs to the Erg/Flt-1 sub-family. Its involvement in human cancers has been widely studied. ERG is linked to normal processes such as mesoderm formation and is found to form functional complexes with Jun/Fos, with the resulting ternary complexes regulating expression of proteins such as metalloprotease-1 (MMP-1) and MMP-3.

EWS-ERG, or EWS-Flt-1 fusion, is a characteristic of Ewing's sarcoma. TMPRSS2-ERG fusion, which occurs on account of translocations and interstitial deletions, is implicated in aggressive forms of prostate cancer. Eighty percent of prostate tumors contain genomic fusions of TMPRSS2 and members of the ETS family of transcription factors. Of these, about 50% contain TMPRSS2-ERG fusions. Interestingly, prostate cancers with TMPRSS2-ERG fusion have been found to have five morphological features: blue-tinged mucin, cribriform growth pattern, macronucleoli, intraductal tumor spread, and signet-ring cell features. ERG overexpression is associated with aggressive tumor behavior and patient survival in prostate cancer. The ERG antibody labels endothelial cells, lymphocytes and prostate cancer cells.

### PRINCIPLE OF THE PROCEDURE

The identification of the antigen on the FFPE tissues is carried out using the above stated antibody. The antigen and antibody complex is visualized using an enzyme coupled (HRP/AP) secondary antibody with specific binding to the primary antibody, this complex is visualized by the enzymatic activation of the chromogen resulting to a visible reaction production of the antigenic site. Each and every step involves precise time and optimal temperature and the results are interpreted using a light microscope by a qualified and trained pathologist.

### REAGENT PROVIDED

**Concentrated format:** Antibody to ERG is affinity purified and diluted in antibody diluent with 1% bovine serum albumin (BSA) and 0.05% of sodium azide (NaN<sub>3</sub>).

**Recommended dilutions:** 1:25 – 1:50

The antibody dilution and protocol may vary depending on the specimen preparation and specific application. Optimal conditions should be determined by individual laboratory.

**Pre-diluted format:** PathnSitu's ready to use antibodies are pre-titrated to optimal staining conditions. Further dilution will affect the efficacy of the antibody and may yield to sub-optimal staining.

**Immunogen:** A synthetic peptide corresponding to residues on the C-terminus in human ERG protein.

DS-PR044-A.

Page 1 of 2

#### TROUBLESHOOTING

1. Follow the antibody specific protocol recommendations according to data sheet provided
2. Tissue staining is dependent on the handling and processing of the tissue prior to staining. Improper fixation, tissue processing, antibody freezing and thawing, washing, drying, heating, sectioning or contamination with other tissues or fluids may produce artifacts, antibody trapping or inaccurate results
3. Do not allow the section to dry out during the entire IHC process
4. Excessive or incomplete counterstaining may compromise the interpretation of the results
5. If unusual results occur, contact PathnSitu's Technical Support at +91-40-2701 5544 or E-mail: [techsupport@pathnsitu.com](mailto:techsupport@pathnsitu.com)

#### LIMITATIONS AND WARRANTY

Authorized and skilled/trained personnel only may use the product. The clinical interpretation of any test results should be evaluated within the context of the patient's medical history and other diagnostic test results. A qualified trained pathologist must perform the evaluation of the test results. There are no warranties, expressed or implied, which extend beyond the description. PathnSitu is not liable for property damage, personal injury, time or effort on economic loss caused by this product.

#### BIBLIOGRAPHY

1. Reddy ES, *et al.*: *Proc Natl Acad Sci U S A* 1987, 84:6131-6135
2. Oikawa T: *Cancer Sci* 2004, 95:626-633
3. Birdsey GM, *et al.*: *Blood* 2008, 111:3498-3506
4. Iwamoto M, *et al.*: *Dev Biol* 2007, 305:40-51
5. Hermans KG, *et al.*: *Cancer Res* 2006, 66:10658-10663
6. FitzGerald LM, *et al.*: *BMC Cancer* 2008, 8:230
7. Park K, *et al.*: *Neoplasia* 2010, 12:590-598
8. Mosquera JM, *et al.*: *J Pathol* 2007, 212:91-101
9. Mosquera JM, *et al.*: *Clin Cancer Res* 2008, 14:3380-3385
10. Kumar-Sinha C, *et al.*: *Nat Rev Cancer* 2008, 8:497-511


ERG, EP111 antibody has been created by Epitomics Inc., using Epitomics proprietary rabbit monoclonal antibody technology covered under Patent No.'s 5,675,063 and 7,402,409.

#### EXPLANATION OF SYMBOLS

LOT- Lot number / Batch number



**IVD** *In vitro* diagnostic use



Storage limitation